Irinotecan API is a pharmaceutical-grade topoisomerase I inhibitor widely used in the treatment of metastatic colorectal cancer and various other solid tumors. It is a semi-synthetic derivative of camptothecin and functions as a prodrug that is converted to its active metabolite, SN-38, which inhibits DNA topoisomerase I, preventing DNA replication and inducing cancer cell death.
Irinotecan is commonly used alone or in combination chemotherapy regimens such as FOLFIRI for colorectal cancer and has demonstrated efficacy in the treatment of gastrointestinal and other advanced malignancies.
Manufactured under WHO-GMP-certified facilities, our Irinotecan API is produced using advanced pharmaceutical manufacturing technologies to ensure exceptional purity, stability, and batch-to-batch consistency. Every batch undergoes comprehensive quality testing and is supplied with Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and complete regulatory documentation.
Irinotecan API is used in injectable pharmaceutical formulations for the treatment of metastatic colorectal cancer and other advanced solid tumors.
Irinotecan is converted into its active metabolite SN-38, which inhibits DNA topoisomerase I, preventing DNA replication and leading to apoptosis of rapidly dividing cancer cells.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation with every shipment.
Yes. We supply Irinotecan API in commercial quantities with worldwide export support and customized packaging.
Get Bulk Quote via WhatsApp